Research Topic

The State-of-Art in Immuno-oncology, what to do with Glioblastoma?

About this Research Topic

Gliomas are the most common primary tumors of the central nervous system, accounting for 27% of brain tumors and 80% of malignant brain tumors. More than half of malignant primary brain tumors are glioblastomas with expected media survival around 56 weeks. Recently, PD-1/PD-L1 antibody adjuvant immunotherapy ...

Gliomas are the most common primary tumors of the central nervous system, accounting for 27% of brain tumors and 80% of malignant brain tumors. More than half of malignant primary brain tumors are glioblastomas with expected media survival around 56 weeks. Recently, PD-1/PD-L1 antibody adjuvant immunotherapy gave new hope for current glioblastoma patients. And chimeric antigen receptor (CAR) engineered T cells and NK cells are becoming a novel therapeutic strategy for the treatment of glioblastomas. The microglia-mediated immune-resistance still holds another side of this issue. Therefore, an urgent need to dig deeper within any aspect of immuno-oncology remains.

In recent years, the development of gene sequencing technologies, such as single-cell sequencing and ATAC sequencing, provided a deeper vision of gene expression landscape at the single-cell level. Novel therapeutics aim at enhancing the activity of CD8 T cells and suppressing the immuno-suppressive environment of cancer. Furthermore, novel nano-therapeutic systems can cross the blood-brain-barrier to mimic the cytotoxicity of CD8 positive T cells by delivering granzyme B nanoparticles. These new therapeutics are currently used to target subcutaneous cancers and could be potentially used in brain tumors.

This Research Topic focuses on every aspect of immunology in glioblastoma, including but not limited to, novel technology and bioinformatics in sequencing and proteomics, nanotechnology for brain tumors and immuno-modulation, novel mechanisms of immune-resistance, molecular markers,surgical technology, drug treatment, chemotherapy and CAR-T cell therapy of glioblastoma. The purpose of this Research Topic is to focus on the state-of-art in immune-oncology and to bridge immunology and the therapeutics of glioblastoma.

We welcome authors to submit Original Research, Review, and Perspective articles focusing on:

1. Novel technology and bioinformatics in sequencing and proteomics, single-cell sequencing and ATAC-sequencing in the expression landscape of immune cells in glioblastoma
2. The bioinformatics, molecular markers, subtyping, and predictive factors associated with immunotherapy of glioblastoma
3. Nanotechnology for the treatment of glioblastoma and immuno-modulation
4. Chemotherapy, radiotherapy, adjuvant therapeutics with immuno-check point blockage and CAR-T therapy are warmly welcome
5. Novel mechanisms of immune resistance to glioblastoma


Keywords: Glioma, immunology, sequencing, nanoparticle, chemotherapy,bioinformatics


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Recent Articles

Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

12 July 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

12 July 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..